ROLE SUMMARY
The Associate Director of Biostatistics will provide statistical support in one or more rare disease therapeutic areas (hematology, cardiology, nephrology, metabolic, or neurology), including pre-clinical and clinical development planning and execution for multiple indications in Pfizer’s expanding Rare Disease Research Unit. The position will be accountable for the robust planning and execution of (pre-)clinical development programs across numerous indications and therapeutic modalities (gene therapy, mRNA, small molecule, and biologics). The Associate Director will provide strategic input and leadership in relevant statistical areas such as external control matching, composite endpoint development, and other topics inherent in small-sample drug development.
ROLE RESPONSIBILITIES
Collaborate with various cross-functional scientists in the design, analysis and reporting of laboratory and early clinical studies in rare diseases
Core member of scientific teams responsible for determining strategy and delivering results in a timely and high-quality environment
Interact with internal and external experts to assure sound quantitative approaches are applied to collection and analysis of a wide variety of data types
Contribute to innovative statistical thinking and methods to help drive the Model Informed Drug Development paradigm within Pfizer. Central to this approach in the rare disease setting is the systematic review and incorporation of prior information (utilizing Bayesian methods as appropriate), statistical model building and simulation, and rigorous and robust use of external historical control data
Frequently interact and engage with regulatory agencies regarding accelerated clinical development options for indications that have substantial unmet medical need
Ensure rigorous approaches are taken to ensure good scientific practices are followed: excellent statistical methods utilized and documented in protocols, analysis plans and manuscripts, and assay methods are appropriately blinded, randomized and designed to meet clear objectives
Use statistical expertise to influence both internal and external reports and presentations, with the aim to improve the quality of internal decision making and increase our influence on the external environment
QUALIFICATIONS
Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.?
MSc (PhD preferred) in Statistics, Biostatistics, or related field
Minimum of 6 years’ experience applying statistical methods in the pharmaceutical industry, with early clinical (Phase I and Phase II) and translational experience in rare disease indications a definite advantage
Experience with modeling and simulation and expertise in Model Informed Drug Development (MIDD) principles
Demonstrated strong communication skills, both oral and written
Ability to proactively influence teams with innovative clinical development strategy
Demonstrated competency with the design, implementation, analysis and reporting of clinical trials
New York, New York
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names.
Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.